October 29, 2019 09:52 AM EDT

Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T

Kathy Wong

Editor

→ Regeneron and Sanofi‘s Dupixent — a king in the eczema therapy sector — has cinched its third type 2 inflammatory disease approval in the EU …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T

Kathy Wong

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Dupix­ent cleared for chron­ic rhi­nos­i­nusi­tis in EU; FDA grants RMAT sta­tus to CARs­gen's CAR-T

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Dupixent cleared for chronic rhinosinusitis in EU; FDA grants RMAT status to CARsgen's CAR-T